Lombard Medical has announced the appointment of Raymond Wayne Cohen as non-executive chairman of the company, with immediate effect.
Cohen has held several chairman and CEO positions on the boards of both publicly listed and private life sciences companies in the USA and Europe, according to a company release.
He is currently non-executive chairman of Jenavalve Technology and Syncroness. He is also a non-executive director of BioLife Solutions and LoneStar Heart.
From mid 2010 to late 2012, Cohen served as chief executive officer of Vessix Vascular, a developer of a novel percutaneous radiofrequency balloon catheter renal denervation system used to treat uncontrolled hypertension. In November 2012, during his tenure as CEO, the company was acquired by Boston Scientific in a structured transaction valued at up to US$425 million.
Announced in April, John Rush stepped down as non-executive chairman following the US Food and Drug Aministration (FDA) approval for Aorfix in the USA. John Rush remains an active and committed member of the Board as a Non-executive Director, according to the company.
CEO of Lombard Medical, Simon Hubbert, commented: “The board is delighted to appoint a chairman of Raymond’s calibre and experience. He brings with him extensive knowledge of the medical device sector in the US and international markets, which will serve the company well as it executes its strategy. We also thank John for his leadership over the last few years and are pleased he will remain with the company as a valued member of the board.”